Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-α

Blood

Volumn 92, Issue 11, 1998, Pages 4059-4065

  Mahon, F X ^b   Faberes C ^b   Pueyo, S ^b   Cony Makhoul, P ^b   Salmi, R ^b   Boiron, J M ^b   Marit, G ^b   Bilhou Nabera, C ^b   Carrere A ^b   Montastruc, M ^b   Pigneux, A ^b   Bernard, Ph ^b   Reiffers, J ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032402142     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.11.4059     Document Type: Article

References (31)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T; Chronic myelocytic leukemia: clonal origin in a stem cell common to granulocyte, platelet and monocyte/macrophage. Am J Med 63:125, 1977
2. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
3. Shtivelman E, Lifshitz B, Gale RP, Cananii E: Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315:550, 1985
4. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myeloid leukemia in mice by P210 bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
5. Malinge MC, Mahon FX, Daheron L, Kitzis A, Delfau MH, Guilhot F, Tanzer J, Grandchamp B: Quantitative determination of the hybrid bcr-abl mRNA in patients with chronic myelogenous leukemia under Interferon therapy. Br J Haematol 82:701, 1992
6. Clift R, Appelbaum F, Thomas E: Bone marrow transplantation for chronic myeloid leukemia. Blood 83:2752, 1994
7. McGlave Ph, Beatty P, Ash R, Hows JM: Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: Results in 102 cases. Blood 75:1728, 1990
8. Bhatia R, Verfaillie CM, Miller JS, McGlave Ph: Autologous transplantation therapy for chronic myelogenous leukemia. Blood 89:2623, 1997
9. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Intern Med 122:254, 1995
10. The Italian cooperative study group on chronic myeloid leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
11. Allan NC, Richard SM, Shepherd PCA, on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia: UK Medical Reseach Council randomised, multicentre trial of interferon-α n1 for chonic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
12. Ohnishi K, Ohno R, Tomonoga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawahi S, Tsubaki K: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906, 1995
13. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA: Prolonged subcutaneous administration of recombinant α 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronicphase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
14. Hehlmann R, Heimpel H, Hasford J, Kolb Hj, Pralle H, Hossfeld DK, Queiber W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram Cr, Griebhammer M, Bergmann L, Essers U, Falge C, Queiber U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg Ur, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prÿmmer O, Thiele J, Buhr T, Carbonell F, Ansari H, and The German CML Study Group: Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
15. Montastruc M, Mahon FX, Fabères C, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Puntous M, Pigneux A, Boiron JM, Bernard Ph, Salmi R, Braustet A, Reiffers J: Response to recombinant Interferon alpha in patients with chronic myelogenous leukemia in a single center: Results, analysis of predictive factors. Leukemia 9:1997, 1995
16. Kantarjian H, Dixon D, Keating MJ: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441, 1988
17. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Rubertson JE, Tso CY, Braum TJ, Clarkson BD, Cervantes F, Rozman C, The Italian Cooperative CML Study Group: Prognostic discriminations in "good risk" chronic granulocytic leukemia. Blood 63:789, 1984
18. Braustet A, Reiffers J, Marit G, Fiere D, Jaubert J, Reynaud J. Pris J, Bernard Ph, Charrin C, WenZQ, Berteas MF, Dastugue N, Parlier Y: Hydroxyurea versus interferon alpha-2b in chronic myeloid leukemia: Preliminary results of an open french multicenter randomized study. Eur J Cancer 27:S18 1991 (suppl 4)
19. Reiffers J, Trouette R, Marit G, Montastruc M, Faberes C, Cony-Makhoul P, David B, Bourdeau MJ, Bilhou Nabera C, Lacombe F, Feuillatré-Fabre F, Vezon G, Bernard Ph, Broustet A: Autologous blood stem cell transplantation for chronic granulocytic leukemia in transformation: A report of 47 cases. Br J Haematol 77:339, 1991
20. Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J: Chronic myelogenous leukemia: Haematological remissions with alpha interferon. Br J Haematol 64:87, 1986
21. Talpaz M, Kantarjian H, Mc Credie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha a in chronic myelogenous leukemia. N Engl J Med 314:1065, 1986
22. Christensen E, Schlichting P, Andersen PK, Faverholdt L, Schou G, Pedersen BV, Juhl E, Poulsen H, Tygstrup N: Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables. Scand J Gastroenterol 21:163, 1986
23. Bilhou-Nabera C, Marit G, Gharbi MJ, Salzes S, Mahon FX, Broustet A, Reiffers J, Bernard Ph: Chronic myelocytic leukemia patients achieving complete cytogenetic convention under interferon alpha therapy: Minimal residual disease follow up. Leukemia 9:2067, 1995
24. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Reiter A, Hochhaus A: The German CML-Study Group. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol 97:76, 1997
25. Mahon FX, Montastruc M, Faberes C, Reiffers J: Predicting complete cytogenetic response in chronic myelogenous leukemia (CML) patients treated by recombinant interferon alpha. Blood 84: 3592, 1994 (letter)
26. Mahon FX, Faberes C, Reiffers J: Response to alpha interferon in chronic myelogenous leukemia. Lancet 347:57, 1996 (letter)
27. Hasford J, Baccarrani M, Hehlmann R, Ansari H, Tura S, Zuffa E: Interferon-a and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-a. Blood 87:5384, 1996
28. CML Trialists Collaborative Group: Interferon alpha versus chemotherapy for chronic myeloid leukemia: A meta analysis of seven randomized trials. J Natl Cancer Inst 89:1616, 1997
29. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223, 1997
30. Kantarjian H, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069, 1996
31. Motion J, Gooley T, Hansen JA, Appelbaum FR, Bruemmen B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, Anasetti C: Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394, 1998